Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III–IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial

Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III–IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial

Abstract Background Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common potentially life-threatening inherited kidney diseases. It is the fourth most common cause of end-stage renal disease requiring renal replacement therapy. There are few management options for controlli...

Full description

Bibliographic Details
Main Authors: Jing Gan, Yansheng Wu, Xuezhong Gong, Yiyi Ma, Shengqiang Yu, Jiandong Gao
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Trials
Subjects:
Yinang formulation
Efficacy
Safety
Autosomal dominant polycystic kidney disease
Stages III–IV chronic kidney disease
Randomized controlled trial
Online Access:http://link.springer.com/article/10.1186/s13063-019-3563-5

Internet

http://link.springer.com/article/10.1186/s13063-019-3563-5

Similar Items